<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449019</url>
  </required_header>
  <id_info>
    <org_study_id>DPI</org_study_id>
    <nct_id>NCT01449019</nct_id>
  </id_info>
  <brief_title>The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <acronym>DFG_5</acronym>
  <official_title>The Contribution of Glucagon-like Peptide 1 (GLP-1) to the Entero-insulinar Axis in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the contribution of endogenous Glucagon-like peptide&#xD;
      1 (GLP-1) to the postprandial secretion of insulin and glucagon and the incretin effect in&#xD;
      healthy subjects and patients with type 2 diabetes mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incretin effect</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The incretin effect is the difference between postprandial plasma concentrations of insulin and C-peptide, respectively, and those during the isoglycemic fasting control experiment. The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of glucagon</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of insulin</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of C-peptide</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of Glucagon-like peptide-1(7-36) (GLP-1(7-36))</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of Glucose-dependent insulinotropic polpypeptide (GIP)</measure>
    <time_frame>Area Under Curve (AUC) Time Frame: from 0 to 90 minutes under duodenal meal perfusion</time_frame>
    <description>The AUC is calculated after priming intravenous infusion (saline or exendin(9-39)) and under steady state duodenal meal perfusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>intravenous infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intraduodenal perfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exendin(9-39)amide</intervention_name>
    <description>intravenous infusion of exendin(9-39)</description>
    <arm_group_label>intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>intravenous infusion of saline</description>
    <arm_group_label>intravenous infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>duodenal meal</intervention_name>
    <description>duodenal perfusion of a meal</description>
    <arm_group_label>intraduodenal perfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>duodenal saline</intervention_name>
    <description>duodenal perfusion of saline</description>
    <arm_group_label>intraduodenal perfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female (postmenopausal, surgically sterile or using double-barrier method of&#xD;
             contraception) healthy subjects and patients with type 2 diabetes mellitus (T2DM)&#xD;
&#xD;
          -  must be able to complete a 1 week wash-out of current anti-diabetic medications&#xD;
&#xD;
          -  Age 30-70 years&#xD;
&#xD;
          -  HbA1c (Hemoglobin A1c) ≤11% at screening&#xD;
&#xD;
          -  Body mass index (BMI) &lt;40 kg/m2&#xD;
&#xD;
          -  Patients with type 2 diabetes mellitus (T2DM): Must have a fasting blood glucose of&#xD;
             ≤12.2 mmol/L (240 mg/dL) at screening&#xD;
&#xD;
          -  Able to provide written informed consent prior to study participation&#xD;
&#xD;
          -  Able to communicate well with the investigator and comply with the requirements of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with type 1 diabetes mellitus (T1DM), diabetes as a result of pancreatic&#xD;
             injury, or secondary forms of diabetes (eg Cushing, acromegaly)&#xD;
&#xD;
          -  Need for insulin within the previous 3 months&#xD;
&#xD;
          -  Use of Thiazolidinediones in the previous 4 weeks&#xD;
&#xD;
          -  Significant concomitant disease or complications of diabetes (i.e. nephropathy,&#xD;
             autonomic dysfunction, orthostasis).&#xD;
&#xD;
          -  Treatment with systemic steroids and thyroid hormone (unstable dosage).&#xD;
&#xD;
          -  Patients with any history of gastrointestinal surgery, e.g. partial bowel resections,&#xD;
             partial gastric resections, etc.&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer&#xD;
             if required by local regulation.&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.&#xD;
&#xD;
          -  Significant illness within the two weeks prior to dosing.&#xD;
&#xD;
          -  Past medical history of clinically significant ECG abnormalities or a family history&#xD;
             of a prolonged QT-interval syndrome.&#xD;
&#xD;
          -  History of clinically significant drug allergy; history of atopic allergy (asthma,&#xD;
             urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs&#xD;
             similar to the study drug.&#xD;
&#xD;
          -  history of major gastrointestinal tract surgery such as gastrectomy,&#xD;
             gastroenterostomy, or bowel resection;&#xD;
&#xD;
          -  history or clinical evidence of pancreatic injury or pancreatitis;&#xD;
&#xD;
          -  history or presence of impaired renal function as indicated by abnormal creatinine or&#xD;
             urea val-ues or abnormal urinary constituents (e.g., albuminuria);&#xD;
&#xD;
          -  evidence of urinary obstruction or difficulty in voiding at screening;&#xD;
&#xD;
          -  Polymorphonuclears &lt;1500/µL at inclusion or platelet count &lt; 100,000/μL at screening&#xD;
             and baseline.&#xD;
&#xD;
          -  History of immunocompromise.&#xD;
&#xD;
          -  Evidence of liver disease as indicated by abnormal transaminases and alkaline&#xD;
             phosphatase exceeding twice the upper limit of the normal range, and serum bilirubin&#xD;
             should not exceed the value of 27 µmol/L (1.6 mg/dL).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Schirra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Unit (CRU), Department of Internal Medicine, Campus Großhadern, Clinical Center of Ludwig-Maximilians-University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Maximilians-University, Clinical Research Unit</name>
      <address>
        <city>Munich</city>
        <zip>80999</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research unit, Dept. of Internal Medicine II - Großhadern, University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>October 2, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Joerg Schirra</investigator_full_name>
    <investigator_title>Principal investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>Exendin(9-39)</keyword>
  <keyword>Insulin</keyword>
  <keyword>Glucagon</keyword>
  <keyword>T2DM</keyword>
  <keyword>incretin effect</keyword>
  <keyword>human physiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

